Healthcare sector private equity firm Ampersand Capital Partners revealed on Thursday that it plans to acquire Vibalogics GmbH, a contract development and manufacturing organisation (CDMO) in Cuxhaven, Germany.

The financial terms of the agreement were not disclosed by the companies.

Ampersand said that its growth investment will be used to expand Vibalogics' capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products.

Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies and vaccines. With a specific focus on viruses, live bacteria and aseptic processing, the company's 50 employees work in full compliance with international GMP standards in a BSL-2 classified state of the art, 27,000 sq ft (2,500 m2) facility in Cuxhaven, Germany.